Advertisement: TTP Killer 50
23 April, 2019 - 15:20 By Tony Quested


Dr Tom Weaver PetMedix

PetMedix is applying 30 years of antibody research and the scientific work of two of its founders, Professor Allan Bradley and Dr Jolyon Martin, to develop new pet therapeutics against a wide range of diseases. 

PetMedix is built from the same world-leading transgenic technology that underpins the most successful and advanced human antibody platforms available today.

Led by founder and CEO, Dr Tom Weaver, PetMedix raised £8 million Series A funding in March 2019 from co-investors Parkwalk Advisors and Digitalis Ventures to grow operations and the team, and begin drug discovery.

Weaver is ex-CEO of Congenica and Bradley the emeritus director of the Wellcome Trust Sanger Institute and one of the brains behind antibodies powerhouse Kymab. 

Job opportunities at PetMedix

Newsletter Subscription

Stay informed of the latest news and features